Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
Revisado por: María José Muñoz Vilches
Grupo de trabajo: Patología Importada
Referencia: Jaime AltchehI, Luis CastroI, Juan C. Dib, et al. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO). PLOS Neglected Tropical Diseases https://doi.org/10.1371/journal.pntd.0008912 January 7, 2021
Ten Years of National Seasonal Surveillance for Severe Complications of Influenza in Australian Children
Revisado por: Marta Cruz Cañete
Grupo de trabajo: Infecciones Respiratorias
Referencia: Teutsch SM, Zurynski YA, Nunez C, et al. Australian Paediatric Surveillance Unit. Ten Years of National Seasonal Surveillance for Severe Complications of Influenza in Australian Children. Pediatr Infect Dis J 2021; 40:191-198
Severity of Illness Caused by Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern in Children: A Single-Center Retrospective Cohort Study
Revisado por: Alfredo Tagarro
Grupo de trabajo: Infecciones Respiratorias
Referencia: Edward PR, Ramon-Redondo R, E. Reyna M, et al. Severity of Illness Caused by Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern in Children: A Single-Center Retrospective Cohort Study. medRxiv 2021.10.23.21265402; doi:https://doi.org/10.1101/2021.10.23.21265402
Invasive Fungal Infections in Immunocompromised Children: Novel Insight Following a National Study
Revisado por: Begoña Carazo
Grupo de trabajo: Infección Fúngica Invasiva
Referencia: Olivier-Gougenheim L, Rama N, Dupont D, et al. Invasive Fungal Infections in Immunocompromised Children: Novel Insight Following a National Study. J Pediatr. 2021;236:204-210. doi:10.1016/j.jpeds.2021.05.016
Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13‑valent (PCV13) pneumococcal conjugate vaccination during 2015–2019
Revisado por: Josefa Ares Alvarez
Grupo de trabajo: Infecciones de manejo ambulatorio
Referencia: Ravinder Kaur, Naoko Fuji, Michael E. Pichichero. Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13‑valent (PCV13) pneumococcal conjugate vaccination during 2015–2019. Eur J Clin Microbiol Infect Dis. 2021 Aug 25. doi: 10.1007/s10096-021-04324-0.
Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial
Revisado por: Cristina Calvo
Grupo de trabajo: Infecciones Respiratorias
Referencia: Bielicki JA, Stöhr W, Barratt S, et al. Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial. JAMA. 2021 Nov 2;326(17):1713-1724. doi: 10.1001/jama.2021.17843.
Changes in the incidence of invasive disease due toStreptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data
Revisado por: David López Martín
Grupo de trabajo: Infecciones bacterianas
Referencia: Brueggemann AB, Jansen van Rensburg MJ, Shaw D, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit Health 2021; 3: e360–70
Antibiotics for lower respiratory tract infection in children presenting in primary care in England (ARTIC PC): a double-blind, randomised, placebo-controlled trial
Revisado por: Carlos Pérez Méndez
Grupo de trabajo: Infecciones Respiratorias
Referencia: Little P, Francis NA, Stuart B, et al. Lancet. 2021 Sep 22;S0140-6736(21)01431-8. doi: 10.1016/S0140-6736(21)01431-8.
